GlassScriptPhysician profile
Harish Gagneja
NPI 1235114786
$577,727.18
in general payments reported to CMS, 2019-2025
58 companies · $44K in 2025
The $44K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $162K · 2021: $47K · 2022: $76K · 2023: $47K · 2024: $124K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Travel and Lodging: $32K · Food and Beverage: $21K · Consulting Fee: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,175 · Honoraria: $1,000 · Education: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,211.04 |
| Travel and Lodging | $31,769.08 |
| Food and Beverage | $20,746.76 |
| Consulting Fee | $10,542.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,175.00 |
| Honoraria | $1,000.00 |
| Education | $662.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $149,461.60 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $125,576.29 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80,155.06 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Medtronic, INC. | $58,638.03 | 2021-2025 | Gi Genius, Pillcam, Endoflip |
| Genzyme Corporation | $46,191.72 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $24,000.99 | 2022-2025 | Dupixent |
| Abbvie INC. | $21,027.01 | 2019-2025 | |
| Redhill Biopharma INC. | $15,411.90 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $11,919.72 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $7,951.09 | 2019-2024 | Rebyota |
| Pfizer INC. | $5,597.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,182.00 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $3,962.19 | 2019-2025 | Entyvio, Gattex |
| Gastrogpo, LLC | $3,231.92 | 2022-2023 | |
| Ferring International Pharmascience Center US | $3,000.00 | 2019 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $2,745.82 | 2021-2024 | Zeposia |
| Wilson Cook Medical Incorporated | $2,184.15 | 2019 | |
| Janssen Scientific Affairs, LLC | $1,703.04 | 2019-2025 | Tremfya, Stelara, Remicade |
| Alfasigma USA, INC. | $1,529.36 | 2020 | |
| Janssen Biotech, INC. | $1,057.74 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Micro-Tech Endoscopy USA, INC. | $1,005.68 | 2019-2020 | |
| Boston Scientific Corporation | $964.53 | 2019-2025 | Exalt Model D, Resolution 360 Clip, Overstitch Nxt Endoscopic Suturing System |
| Ambu INC. | $910.97 | 2021-2024 | |
| Cook Medical LLC | $658.55 | 2019-2023 | Fusion |
| Olympus America INC. | $457.41 | 2022-2025 | Evis Exera III Colonovideoscope, Endoclot Phs, High Definition Lcd Monitor |
| Anx Robotica Corp | $412.02 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $318.22 | 2025 | Iqirvo |
| Creo Medical INC. | $298.17 | 2022-2023 | Speedboat |
| Ardelyx, INC. | $246.13 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $224.77 | 2020-2023 | |
| Ucb, INC. | $213.06 | 2019-2021 | |
| Lilly USA, LLC | $198.08 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $186.14 | 2024-2025 | Vegzelma, Zymfentra |
| Exact Sciences Corporation | $173.55 | 2023 | Cologuard Collection Kit |
| Erbe USA INC | $165.70 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $151.97 | 2024-2025 | Zenpep |
| Pentax of America, INC. | $146.91 | 2022-2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Ethicon US, LLC | $143.39 | 2019-2020 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Gi Supply, INC. | $122.53 | 2021 | |
| Ironwood Pharmaceuticals, INC | $121.93 | 2021-2024 | Linzess |
| Medivators INC. | $108.32 | 2019 | |
| Madrigal Pharmaceuticals | $104.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $101.55 | 2022 | |
| Endogastric Solutions, INC | $94.07 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $86.74 | 2022-2023 | Stelara |
| Iterative Scopes, INC. | $69.72 | 2024 | Skout |
| Intercept Pharmaceuticals, INC. | $64.84 | 2021-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $62.38 | 2022-2023 | Dificid |
| Axonics, INC. | $56.10 | 2020 | |
| Organon LLC | $50.35 | 2023-2024 | Renflexis, Hadlima |
| Qol Medical, LLC | $41.94 | 2021-2022 | |
| Mauna Kea Technologies, INC. | $29.01 | 2019 | |
| Biocon Biologics INC | $22.66 | 2025 | Yesintek |
| Eisai INC. | $20.29 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $16.93 | 2024 | Kristalose |
| Capsovision, INC. | $13.33 | 2024 | Capsocam Plus |
| Conmed Corporation | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Gagneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.